Drug-Eluting Stents Work for Restenosis

Effective treatment for repeat in-stent narrowing

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

En Español

MONDAY, Dec. 27, 2004 (HealthDayNews) -- Drug-eluting stents greatly reduce the risk that arteries will renarrow in patients with in-stent restinosis -- artery narrowing caused by scar tissue -- according to a German study in the January issue of Catheterization and Cardiovascular Interventions.

The study noted that plaque-clogged arteries that are opened with a regular metal stent have a 1-in-3 chance of becoming narrowed again with scar tissue (restinosis). If this problem is treated using a metal stent or balloon angioplasty, the artery will narrow again in half the patients.

This study of 77 patients found a 13 percent rate of repeat in-stent restinosis among patients treated with a drug-eluting stent that slowly releases the drug sirolimus, which prevents formation of scar tissue. The in-stent restinosis repeat rate was 61 percent for patients treated with balloon angioplasty.

At the nine-month follow up, 14 percent of the patients treated with the sirolimus-eluting stent required yet another procedure to open the artery, compared with 32 percent of balloon angioplasty patients.

"Restinosis was dramatically lowered by drug-eluting stents as opposed to balloon angioplasty alone, and that resulted in a dramatic lowering in the major adverse cardiac event rate," researcher Dr. Rainer Hoffman from the University of Aachen said in a prepared statement.

More information

The U.S. Food and Drug Administration has more about stents.

SOURCE: Catheterization and Cardiovascular Interventions, news release, Dec. 27, 2004

--

Last Updated: